Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
A band-aid or bandage in case you want to cover the area where the injection was given
A meta-study that included 9 clinical studies with 911 participants confirmed that over time on average the participants lost some fat (1.33 kg versus 0.57 kg), but after a meta-regression analysis the fat loss was close to zero
What is the expected CAGR of the GLP-1 nutritional support market from 2025 to 2035
Most side effects are mild to moderate and may include temporary nausea or gastrointestinal discomfort, particularly during dose escalation
What It Targets Our AOD-9604 peptides are designed to target: Stubborn body fat and slow fat loss in clients already working on nutrition, steps, and strength training. Mild to moderate central adiposity where clients want incremental support rather than a primary weight-loss medication. Clients who cannot or do not wish to use GLP1s but still want to explore peptide-based metabolic support under a transparent riskbenefit discussion. Aesthetic-focused body recomposition journeys where even small improvements in fatmuscle balance can enhance contouring results
2022, NEJM) for Zepbound
US$ 29.55
US$ 21.71
US$ 27.36
US$ 23.16
US$ 28.28
